Another trial investigated retrospectively the efficacy of NET or NCT in locally advanced lobular breast cancer, a breast cancer subtype which accounts for 10–15% of breast cancer and is often characterized by a higher expression of hormonal receptors, low grading and lower ki67 values if compared to ductal carcinoma [39]. This evidence concerns the gene MKI67 and breast cancer.